Patient experience and practice trends in multiple sclerosis – clinical utility of fingolimod

References

• Novartis PharmaceuticalsFingolimod Prescribing Information2014 Available from: http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdfAccessed December 8, 2014
   Google Scholar
• European Medicines AgencyEuropean Public Assessment Report (EPAR) for Gilenya2014 Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002202/human_med_001433.jsp&mid=WC0b01ac058001d125Accessed December 8, 2014 Gilenya: EPAR: Summary report for the public
   Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362387401 Pivotal Trial FREEDOMS20089952
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGTRANSFORMS Study GroupOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Med2010362402415 Pivotal Trial FREEDOMS20089954
   PubMed Web of Science ®Google Scholar
• HlaTBrinkmannVSphingosine 1-phosphate (S1P): physiology and the effects of S1P receptor modulationNeurology201176S3S821339489
   PubMed Web of Science ®Google Scholar
• BrinkmannVFTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous systemBr J Pharmacol20091581173118219814729
   PubMed Web of Science ®Google Scholar
• BrinkmannVDavisMDHeiseCEThe immune modulator FTY720 targets sphingosine 1-phosphate receptorsJ Biol Chem200227724214532145711967257
   PubMed Web of Science ®Google Scholar
• CohenJAChunJMechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosisAnn Neurol201169575977721520239
   PubMed Web of Science ®Google Scholar
• MehlingMJohnsonTAAntelJKapposLBar-OrAClinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosisNeurology2011768 suppl 3S20S2721339487
   PubMed Web of Science ®Google Scholar
• ChoiJWGardellSEHerrDRFTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor (S1P1) modulationProc Natl Acad Sci U S A2011108275175621177428
   PubMed Web of Science ®Google Scholar
• GrovesAKiharaYChunJFingolimod: direct CNS effects on sphingosine 1-phosphate (S1) receptor modulation and implications in multiple sclerosis therapyJ Neurol Sci20133281–291823518370
   PubMed Web of Science ®Google Scholar
• MullershausenFZecriFCetinCBillichAGueriniDSeuwenKPersistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptorsNat Chem Biol20095642843419430484
   PubMed Web of Science ®Google Scholar
• Van DoornRVan HorssenJVerzijlDSphingosine 1-phosphate receptors 1 and 3 are upregulated in multiple sclerosis lesionsGlia201058121465147620648639
   PubMed Web of Science ®Google Scholar
• ScottLJFingolimod: a review of its use in the management of relapsing-remitting multiple sclerosisCNS Drugs2011867369821790210
   PubMed Web of Science ®Google Scholar
• DevonshireVHavrdovaERadueEWFREEDOMS study groupRelapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomized, placebo-controlled FREEDOMS studyLancet Neurol20121142042822494956
   PubMed Web of Science ®Google Scholar
• GasperiniCRuggieriSDevelopment of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approachDrug Des Devel Ther20126175186
   PubMed Web of Science ®Google Scholar
• GasperiniCRuggieriSMancinelliCRPozzilliCAdvances in the treatment of relapsing-remitting multiple sclerosis – critical appraisal of fingolimodTher Clin Risk Manag20139738523483794
   PubMed Web of Science ®Google Scholar
• MehlingMKapposLDerfussTFingolimod for multiple sclerosis: mechanism of action, clinical outcomes, and future directionsCurr Neurol Neurosci Rep20111149249721789537
   PubMed Web of Science ®Google Scholar
• RommerPSZettlUKKieseierBRequirement for safety monitoring for approved multiple sclerosis therapies: an overviewClin Exp Immunol2013175339740724102425
   PubMed Web of Science ®Google Scholar
• WardMJonesDEGoldmanMDOverview and safety of fingolimod hydrochloride use in patients with multiple sclerosisExpert Opin Drug Saf201413798999824935480
   PubMed Web of Science ®Google Scholar
• KapposLCohenJCollinsWFingolimod in relapsing multiple sclerosis: an integrated analysis of safety findingsMultiple Sclerosis and Related Disorders20143449450425877062
   PubMed Web of Science ®Google Scholar
• BeranRGHegaziYSchwartzRSCordatoDJRebound exacerbation multiple sclerosis following cessation of oral treatmentMult Scler Relat Disord20132325225525877732
   PubMed Web of Science ®Google Scholar
• AlroughaniRAlroughaniRAlmullaALamdhadeSThussuASevere reactivation of multiple sclerosis after discontinuation of fingolimod: an IRIS-associated phenomenonMult Scler Relat Disord201436748
   Google Scholar
• HavlaJBPellkoferHLMeinlIGerdesLAHohfeldRKumpfelTRebound of disease activity after withdrawal of fingolimod (FTY720) treatmentArch Neurol201269226226422332194
   PubMedGoogle Scholar
• GhezziARoccaMABaronciniDDisease reactivation after fingolimod discontinuation in two multiple sclerosis patientsJ Neurol2013260132732923161460
   PubMed Web of Science ®Google Scholar
• RommerPSZettlUKKieseierBRequirement for safety monitoring for approved multiple sclerosis therapies: an overviewClin Exp Immunol2014175339740724102425
   PubMed Web of Science ®Google Scholar
• SingerBAInitiating oral fingolimod treatment in patients with multiple sclerosisTher Adv Neurol Disord20136426927523858329
   PubMed Web of Science ®Google Scholar
• OntanedaDHara-CleaverCRudickRACohenJABermelRAEarly tolerability and safety of fingolimod in clinical practiceJ Neurol Sci20123231–216717223040960
   PubMed Web of Science ®Google Scholar
• ThomasKZiemssenTManagement of fingolimod in clinical practiceClin Neurol Neurosurg2013115suppl 1S60S6424321158
   PubMed Web of Science ®Google Scholar
• ThöneJEllrichmannGOral available agents in the treatment of relapsing remitting multiple sclerosis: an overview of merits and culpritsDrug Healthc Patient Saf20135374723459383
   PubMedGoogle Scholar
• BergerJRVaricella vaccination after fingolimod: a case reportMult Scler Relat Disord20132439139425877852
   PubMed Web of Science ®Google Scholar
• JainNBhattiMTFingolimod-associated macular edema: incidence, detection, and managementNeurology201278967268022371414
   PubMed Web of Science ®Google Scholar
• CoppesOGutierrezIRederATKsiazekSBernardJSevere early bilateral macular edema following fingolimod therapyMult Scler Relat Disord20132325625825877733
   PubMed Web of Science ®Google Scholar
• GoldRComiGPalaceJFIRST Study InvestigatorsAssessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label studyJ Neurol2014261226727624221641
   PubMed Web of Science ®Google Scholar
• CammJHlaTBakshiRBrinkmannVCardiac and vascular effects of fingolimod: mechanistic basis and clinical implicationsAm Heart J2014168563264425440790
   PubMed Web of Science ®Google Scholar
• HorgaACastrilloJMontalbanXFingolimod for relapsing multiple sclerosis; an updateExpert Opin Pharmacother2010111183119620367536
   PubMed Web of Science ®Google Scholar
• FDARevised Drug MonitoringUS Food and Drug Administration2014 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm303192.htmAccessed December 8, 2014
   Google Scholar
• FDAFirst Reported Death on Gilenya: 24hrs Post FDOUS Food and Drug Administration2014 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm284240.htmAccessed December 8, 2014
   Google Scholar
• ThomasKSchrötterHHalankMZiemssenTFingolimod in a patient with heart failure on the background of pulmonary arterial hypertension and coronary artery diseaseBMC Neurol20141412624906818
   PubMed Web of Science ®Google Scholar
• LaroniABrogiDMorraVBEAP InvestigatorsSafety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trialBMC Neurol2014146524690227
   PubMed Web of Science ®Google Scholar
• FaberHFischerH-JWeberFProlonged and symptomatic bradycardia following a single dose of fingolimodMult Scler201319112612822729989
   PubMed Web of Science ®Google Scholar
• SingerBRossAPTobiasKOral fingolimod for the treatment of patients with relapsing forms of multiple sclerosisInt J Clin Pract201165888789521679286
   PubMed Web of Science ®Google Scholar
• CalabresiPARadueEWGoodinDSafety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomized, placebo-controlled, phase 3 trialLancet Neurol201413654555624685276
   PubMed Web of Science ®Google Scholar
• JohnsonTAShamesIKeezerMReconstitution of circulating lymphocyte counts in FTY720-treated MS patientsClin Immunol20101371152020599429
   PubMed Web of Science ®Google Scholar
• RosenstielPVGottschalkRCappielloLZhangYSaidMKapposLLong-term safety of fingolimod: interim evaluation of data from the longterms trialMult Scler Relat Disord20143675225891590
   PubMedGoogle Scholar
• HughesBCascioneMFreedmanMSFirst-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, evaluate patient outcomes (EPOC) study in relapsing multiple sclerosisMult Scler Relat Disord201435620628
   Web of Science ®Google Scholar
• ConzettKBKolmIJelcicIMelanoma occurring during treatment with fingolimod for multiple sclerosis: a case reportArch Dermatol2011147899199221844470
   PubMedGoogle Scholar
• LorvikKBBogenBCorthayAFingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in miceBlood201211992176217722383793
   PubMed Web of Science ®Google Scholar
• KarlssonGFrancisGKorenGPregnancy outcomes in the clinical development program of fingolimod in multiple sclerosisNeurology201482867468024463630
   PubMed Web of Science ®Google Scholar
• JonesBMultiple sclerosis: study reinforces need for contraception in women taking fingolimodNat Rev Neurol201410312524514867
   PubMedGoogle Scholar
• AlwanSChambersCDArmentiVTDessa-SadovnickAThe need for disease-specific prospective pregnancy registry for multiple sclerosis (MS)Mult Scler Relat Disord20154161725787048
   PubMed Web of Science ®Google Scholar
• HoutchensMKKolbCMMultiple sclerosis and pregnancy: therapeutic considerationsJ Neurol201326051202121422926165
   PubMed Web of Science ®Google Scholar
• HellmannMALevNLotanITumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapyJ Neurol Sci20143441–219319725001515
   PubMed Web of Science ®Google Scholar
• PilzGHarrerAWipflerPTumefactive MS lesions under fingolimod: a case report and literature reviewNeurology201381191654165824097813
   PubMed Web of Science ®Google Scholar
• CastropFKowarikMCAlbrechtHSevere multiple sclerosis relapse under fingolimod therapy: incident or coincidence?Neurology2012781292893022402856
   PubMed Web of Science ®Google Scholar
• JanderSTurowskiBKieseierBCHartungH-PEmerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimodMult Scler2012181650165223100527
   PubMed Web of Science ®Google Scholar
• DaelmanLMaitrotAMaaroufAChaunuMPPapeixCTourbahASevere multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawalMult Scler2012111647164922907938
   PubMed Web of Science ®Google Scholar
• HakikiBPortaccioEGianniniMRazzoliniLPastoLAmatoMPWithdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six casesMult Scler201218111636163922829326
   PubMed Web of Science ®Google Scholar
• CentonzeDRossiSRinaldiFGalloPSevere relapses under fingolimod treatment prescribed after natalizumabNeurology201279192004200523035063
   PubMed Web of Science ®Google Scholar
• AlroughaniRAhmedSAl-HashelJThe risk of short-term relapse in patients switching from natalizumab to fingolimodMult Scler Relat Disord201436748749
   Google Scholar
• FDABrain Infection Case. US Food and Drug Administration2014 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm366529.htmAccessed December 8, 2014
   Google Scholar
• CalicZCappelen-SmithCHodgkinsonSJMcDougallACuganesanRBrewBJTreatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fin-golimod after discontinuation of natalizumabJ Clin Neurosci201422359860025523125
   PubMed Web of Science ®Google Scholar
• KhatriBOPelletierJKapposLEffect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs interferon B-1a intramuscular: subgroup analyses of the trial assessing injectable interferon vs. fingolimod oral in relapsing-remitting multiple sclerosis (TRANSFORMS)Mult Scler Relat Disord20133335536325876473
   PubMed Web of Science ®Google Scholar
• KhatriBBarkhofFComiGTRANSFORMS Study GroupComparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomized extension of the TRANSFORMS studyLancet Neurol201110652052921571593
   PubMed Web of Science ®Google Scholar
• RadueEWO’ConnorPPolmanCHFTY720 Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) Study GroupImpact of fingolimod therapy on magnetic resonance imaging outcomes in patients with multiple sclerosisArch Neurol201269101259126922751847
   PubMedGoogle Scholar
• YamoutBKhourySZeineddineMHouranyREfficacy and safety of fingolimod treatment in multiple sclerosis: the clinical experience of the AUBMC Multiple Sclerosis Center in LebanonMult Scler Relat Disord20143674925891584
   PubMedGoogle Scholar
• ZiemmsenTDiaz-LorenteMAbdelkaderMCornelissenCPAN-GAEA: post-authorization Noninterventional German safety Study of Gilenya in relapsing-remitting multiple sclerosis (RRMS) patients: a 24-month interim analysis of a German five-year fingolimod registry studyMult Scler Relat Disord201436751
   Google Scholar
• FazekasFBajenaruOBergerTHow does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?Front Neurol201341023641231
   PubMed Web of Science ®Google Scholar
• HansonKAAgashivalaNWyrwichKWRaimundoKKimEBrandesDWTreatment selection and experience in multiple sclerosis: survey of neurologistsPatient Prefer Adherence2014841542224729689
   PubMed Web of Science ®Google Scholar
• OntanedaDCohnSFoxRJRisk stratification and mitigation in multiple sclerosisMult Scler Relat Disord20143563964925221744
   PubMed Web of Science ®Google Scholar
• FoxEEdwardsKBurchGOutcomes of switching directly to oral fingolimod from injectable therapies: results of the randomized, open-label, multicenter, evaluate patient outcomes (EPOC) study in relapsing multiple sclerosisMult Scler Relat Disord201435607619
   PubMed Web of Science ®Google Scholar
• HavlaJTackenbergBHellwigKFingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosisJ Neurol201326051382138723266894
   PubMed Web of Science ®Google Scholar
• de SezeJOngagnaJCCollonguesNReduction of the washout time between natalizumab and fingolimodMult Scler2013199124823722322
   PubMed Web of Science ®Google Scholar
• HalpernRAgarwalSBortonLOneacreKLopez-BresnahanMVAdherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysisAdv Ther201128976177521870169
   PubMed Web of Science ®Google Scholar
• AgashivalaNWuNAbouzaidSCompliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort studyBMC Neurol20131313824093542
   PubMed Web of Science ®Google Scholar
• TanHCaiQAgarwalSStephensonJJKamatSImpact of adherence to disease-modifying therapies on clinical and economic outcomes among patients with multiple sclerosisAdv Ther2011281516121153000
   PubMed Web of Science ®Google Scholar
• MenzinJCaonCNicholsCWhiteLAFriedmanMPillMWNarrative review of the literature on adherence to disease-modifying therapies among patients with multiple sclerosisJ Manag Care Pharm2013191 suppl AS24S4023383731
   PubMed Web of Science ®Google Scholar
• Therapeutic decision making in multiple sclerosis: best practice algorithms for the MS care clinicianInt J MS Care201416suppl 613624688349
   PubMedGoogle Scholar